Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.53 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.50 |
| ▸ | FLT1 | P17948 | 2/20 | 0.50 |
| ▸ | PARP1 | P09874 | 3/20 | 0.49 |
| ▸ | METAP1 | P53582 | 2/20 | 0.47 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 4/20 | 0.45 |
| ▸ | PDE5A | O76074 | 3/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939186 | 0.79 | NUDT1 (0.53) | NUDT1ATAD2FGFR1FLT1PARP1 | |
| SCHEMBL1133963 | 0.79 | NUDT1 (0.62) | NUDT1ATAD2FGFR1FLT1PARP1 | |
| SCHEMBL3209670 | 0.79 | NUDT1 (0.53) | NUDT1ATAD2FGFR1FLT1PARP1 | |
| SCHEMBL805045 | 0.77 | NUDT1 (0.60) | NUDT1METAP1METAP2HPGDNPC1 | |
| SCHEMBL10375895 | 0.75 | NUDT1 (0.49) | NUDT1FGFR1FLT1PARP1METAP1 | |
| SCHEMBL8312963 | 0.74 | NOS1 (0.44) | PARP1DAOKMT2A | |
| SCHEMBL323981 | 0.73 | NUDT1 (0.60) | NUDT1FGFR1FLT1METAP1METAP2 | |
| SCHEMBL10285823 | 0.73 | MGAM (0.50) | PARP1AURKA | |
| SCHEMBL1170747 | 0.72 | METAP1 (0.72) | NUDT1FGFR1FLT1METAP1METAP2 | |
| SCHEMBL30617972 | 0.72 | PLAUR (0.61) | FGFR1HPGDNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056863-B2 | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof | H. LUNDBECK A/S (DK) | 2015-06-16 | — | — | US | disclosed |
| US-20140235645-A1 | Pyridine Compounds and Uses Thereof | H. LUNDBECK A/S (DK) | 2014-08-21 | — | — | US | disclosed |
| EP-2763989-A1 | PYRIDINE COMPOUNDS AND USES THEREOF | H. Lundbeck A/S (DK) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013034761-A1 | PYRIDINE COMPOUNDS AND USES THEREOF | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235645-A1 | Pyridine Compounds and Uses Thereof | ATP6V1B2, NDUFS5, MT-ND5 | NUDT1 279/4885ATAD2 2587/4885FGFR1 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.